Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Cancer Insights

- PMLiVE

Smarter science, sharper strategy: Expert insights from ASCO® 2026

As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?

Inizio

- PMLiVE

The Future of Decisioning

The traditional model for gathering insights is reaching a breaking point. Healthcare Professionals (HCPs) are increasingly time-poor and difficult to reach. Simultaneously, the costs of traditional market research are rising,...

Havas Lynx

Doctor speaking to patient

Permission to pause: making treatment breaks part of the cancer care conversation

Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.

Cuttsy + Cuttsy

- PMLiVE

Havas Lynx expands Claire Knapp’s remit to oversee Havas Lynx New York

In addition, Bruno Rebelo is appointed to the NY office as Chief Creative Officer

- PMLiVE

Key takeaways from ASCO® 2026

Following ASCO® 2026, Inizio's experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year's congress revealed for pharmaceutical organisations. Together, they...

Inizio

- PMLiVE

Webcast | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026

Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.

Inizio

- PMLiVE

Pfizer and Innovent Biologics agree on deal worth up to $10.5bn

The companies plan to research and develop 12 new cancer treatments

- PMLiVE

Havas Lynx celebrates 40 years of impact

Starting out in 1986 as a team of two in Manchester’s Northern Quarter, Havas Lynx has much to celebrate, having grown to become an international healthcare communications agency with offices...

Havas Lynx

- PMLiVE

One-carbon Therapeutics collaborates with Tempus in cancer treatment

The treatment is currently being evaluated in a phase 1/2 multicentre clinical study

- PMLiVE

Gilead to acquire Tubulis for up to $5bn

The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need

- PMLiVE

Connecting through the chaos – why medical affairs needs creative problem-solving

By Ali Walsh

- PMLiVE

Vibrant Therapeutics raises $61m in funding to advance intelligent therapeutics pipeline

The financing includes new investors Pfizer Ventures and Apricot Capital, bringing the total capital raised to $100m

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links